Table 5. Annual treatment cost of each migraine patient with respect to a different class of anti-migraine drugs.
| Migraine therapy | Median cost for Continuers | Median cost for Switchers | Median cost for Discontinuers | Median cost for study cohort | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| PKR1 ± IQR2 | USD3 ± IQR | PKR ± IQR | USD ± IQR | PKR ± IQR | USD ± IQR | PKR ± IQR | USD ± IQR | ||
| NSAIDs | 4837 ± (324–6459) | 30.9 ± (2.0–41.2) | 9232 ± (782–13641) | 58.9 ± (4.9–87.1) | 1181 ± (110–1478) | 7.5 ± (0.7–9.4) | 6824 ± (783–9457) | 43.6 ± (5.0–60.4) | <0.001 |
| Combination analgesics | 9046 ± (1420–12765) | 57.8 ± (9.0–81.5) | 26520 ± (9342–32788) | 169.4 ± (59.6–209.5) | 3055 ± (722–4267) | 19.5 ± (4.6–27.2) | 25756 ± (8644–34611) | 164.5 ± (55.2–221.1) | 0.004 |
| Triptans | 56823 ± (8129–74573) | 363.0 ± (51.9–476.5) | 7348 ± (2052–11753) | 46.9 ± (13.1–75.0) | 9211 ± (1890–13653) | 58.8 ± (12.0–87.2) | 36091 ± (9566–51467) | 230.6 ± (61.1–328.8) | 0.006 |
| Triptans + NSAIDs | 58774 ± (9266–74785) | 375.5 ± (59.2–477.8) | 32558 ± (6705–45345) | 208.0 ± (42.8–289.7) | 13676 ± (1876–17543) | 87.3 ± (11.9–112.0) | 47754 ± (8671–62785) | 305.1 ± (55.4–401.1) | 0.002 |
| Prophylaxis drugs | 7934 ± (780–12793) | 50.6 ± (4.9–81.7) | 11466 ± (1009–15786) | 73.2 ± (6.4–100.8) | 6389 ± (590–12764) | 40.8 ± (3.7–81.5) | 10056 ± (844–15775) | 64.2 ± (5.3–100.7) | 0.004 |
| Total Median Cost | 11267 ± (3732–18790) | 71.9 ± (23.8–120.0) | 12445 ± (8922–18897) | 79.5 ± (57.0–120.7) | 5263 ± (732–8642) | 33.6 ± (4.6–55.2) | 22674 ± (7764–31567) | 144.8 ± (49.6–201.7) | <0.001 |
| Total cost | 148931.2 | 951.6 | 105823.1 | 676.1 | 34992.3 | 223.5 | 145127 | 927.3 | <0.001 |
1Pakistani rupees
2Interquartile range
3United States Dollar
4USD = 156.50 PKR (At: 25-Sep-2019)